COMP-16. CORRELATING MGMT PROTEIN LEVEL WITH TEMOZOLOMIDE RESPONSE IN GLIOBLASTOMA PATIENTS USING MASS SPECTROMETRY

Glioblastoma (GBM) is an aggressive primary brain tumor with median progression-free survival (PFS) of 7 months and median overall survival (OS) of 15 months. Standard treatment at diagnosis consists of surgery, radiation and temozolomide (TMZ). O-6-methylguanine DNA methyltransferase (MGMT) modulat...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Neuro Oncol
Hoofdauteurs: Yan, Dongyao, Schaff, Lauren, Cecchi, Fabiola, Benz, Steve, Rosenblum, Marc, Hembrough, Todd, Lin, Andrew
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2018
Onderwerpen:
Abstracts
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6217142/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.271
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items